NCT00290017

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Point Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Conditions

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Neoplasms, Lung
• Neoplasms, Pulmonary

Interventions

Type	Name	Description
DRUG	talabostat
DRUG	pemetrexed

Timeline

• Start date: 2006-02-01
• First posted: 2006-02-10
• Last updated: 2007-06-08

Locations

101 sites across 1 country: United States